RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

The FDA granted accelerated approval to Rocket Pharmaceuticals' gene therapy Kresladi for severe leukocyte adhesion deficiency-I (an ultra-rare disease). Despite the approval — a regulatory positive for the company’s product portfolio and potential revenue visibility in a niche indication — Rocket's shares fell, indicating investor concerns or profit-taking; this is a company-specific development likely to move the stock but with limited wider market impact.

Analysis

The FDA granted accelerated approval to Rocket Pharmaceuticals' gene therapy Kresladi for severe leukocyte adhesion deficiency-I (an ultra-rare disease). Despite the approval — a regulatory positive for the company’s product portfolio and potential revenue visibility in a niche indication — Rocket's shares fell, indicating investor concerns or profit-taking; this is a company-specific development likely to move the stock but with limited wider market impact.